GlassScriptPhysician profile
Robert D Galiano
NPI 1255351938
$123,191.66
in general payments reported to CMS, 2019-2025
23 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $202 · 2021: $1,984 · 2022: $1,226 · 2023: $27K · 2024: $38K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Travel and Lodging: $23K · Food and Beverage: $3,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $63,062.50 |
| Travel and Lodging | $23,416.94 |
| Food and Beverage | $3,736.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $61,279.88 | 2019-2025 | |
| Smith+Nephew, INC. | $58,684.26 | 2019-2025 | Pico, Pico 7, Pico 14 |
| Mentor Worldwide LLC | $944.15 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Tepha INC | $420.99 | 2019 | |
| Ets Wound Care LLC | $414.48 | 2023-2025 | Mirragen Advanced Wound Matrix |
| Avita Medical Americas, LLC | $284.20 | 2024-2025 | Permeaderm, Cohealyx, Recell |
| Integra Lifesciences Corporation | $200.98 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Davol INC. | $196.73 | 2024-2025 | Arista Ah Flexitip, Arista |
| Acera Surgical, INC. | $131.29 | 2019-2025 | Restrata Wound Matrix |
| Depuy Synthes Sales INC. | $115.92 | 2025 | Matrixcombo, Trumatch, Matrixorthognathic |
| Kci USA, INC. | $101.11 | 2021-2023 | Prevena, V.A.C. Dermatac, V.A.C. Veraflo |
| Solventum Corporation | $85.42 | 2024-2025 | V.A.C. Veraflo Cleanse Choice, V.A.C. Dermatac, Prevena Restor Bellaform |
| Abbvie INC. | $66.03 | 2022-2024 | |
| Allergan, INC. | $47.82 | 2020-2022 | |
| Galderma Laboratories, L.P. | $37.33 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $36.14 | 2025 | Daxxify |
| Polynovo North America LLC | $36.06 | 2022-2023 | |
| Axogen | $33.85 | 2023 | Avance Nerve Graft |
| Kerecis Limited | $26.30 | 2022 | |
| Aroa Biosurgery Incorporated | $24.95 | 2023 | |
| Innovation Technologies INC | $23.77 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$94,211.28 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Galiano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.